Objectives This paper describes cardiotoxicity and cancer treatment-related cardiac dysfunction (CTRCD). Long-term sequelae of treatment are important, and changing, and may manifest when a patient is under the care of a supportive care service.
Methods Key messages for supportive and palliative care clinicians are outlined to facilitate identification and management of CTRCD.
Results Not all cardiotoxicity is alike. Types of cardiotoxicity, cardiac complications of immunotherapy, the challenge of autonomic nervous system dysfunction in cancer and management of cardiotoxicity are highlighted.
Conclusions The key strategies are early detection of cardiotoxicity, monitoring for development of CTRCD during treatment and surveillance in survivorship.
- heart failure
- clinical decisions
Data availability statement
All data relevant to the study are included in the article.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors BB contributed conception and design of the manuscript, undertook the literature review, analysed and interpreted the data, wrote the initial draft, revised the manuscript, and approved the version of the manuscript to be published. RM gave advice regarding the design and initial draft of the manuscript, revised the manuscript critically for intellectual content and approved the version of the manuscript to be published. BB is guarantor.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; internally peer reviewed.